Study Of NPEPL1 As A Biomarker Of Poor Prognosis In Renal Clear Cell Carcinoma

Objective: With the data from the bio-info database and our own clinical collection,combined with the immunohistochemical and q PCR assays,we carried out the study on NPEPL1’s expression in the renal clear cell cancer and probed NPEPL1’s diagnostic value and its relationships with clinicopathological parameters and the possibility of using it as a biomarker to predict the renal clear cell cancer’s prognosis.Methods: We collected 75 paraffin sections of patients with renal clear cell carcinoma who underwent radical nephrectomy or partial nephrectomy in the Department of Urology,the Second Affiliated Hospital of Kunming Medical University from June 2014 to December 2017.We also collected fresh tissue from 14 pairs of patients who underwent radical nephrectomy or partial nephrectomy for renal cancer from December 2022 to February 2023 A postoperative follow-up was implemented and the patient’s basic clinical information was being collected regularly.Went through immundohistochemistry,and were valued by real-time quantitive q PCR to determine the NPEPL1’s expression.Data from TCGA and GTEx databases was used to analyze the expression levels of NPEPL1 in various cancers and its distinctive expression in CCRCC and the cancer’s neighboring tissue;the receiver operation characteristic curve(ROC)was used to evaluate the diagnostic value of NPEPL1 in CCRCC’s treatments;the clinicopathologic data was used to study the correlation between NPEPL1 expression and various clinical parameters.NPEPL1’s prognostic value was appraised with the help of Kaplan-Meier(K-M)survival curve,cox univariate regression and nomogarm model;R packets were used to analyze RNA sequences and identify in the differently expressed genes(DEGs)between high and low NPEPL1 expression tissues;meanwhile,GO and KEGG enrichments of the DEGs were conducted to interpret the relevant biological process,molecular function,cell composition and signal route,and finally estimate the possible underlying principle and action mechanism involved.Results: Our analytic work on the data from TCGA database and the immunohistochemical test results of patients ’pathological tissues displayed that NPEPL1 was significantly higher-expressed in the CCRCC’s tissue than its neighboring tissue(p<0.001).q PCR results showed that NPEPL1 expressed highly in the cancer tissue and the difference was statistically significant(p<0.05).Our ROC curve exhibited that NPEPL1 had a noteworthy diagnostic efficacy(AUC values were all > 0.8),indicating it could be used to distinguish effectively the cancerous tissue from its neighboring tissue.The expression of NPEPL1 was closely correlated with how the cancer is stated,such as T staging or M staging.The study’s K-M survival curve showed that the overall survival time with high expression of NPEPL1 was significantly shortened.Our cox univariate regression analysis showed that NPEPL1 expression is not only associated with prognosis but it can be used as an independent risk factor to predict the patient’s survival.Both the Nomogorm model with the pathological parameters and its calibration map indicated NPEPL1’s reliability of being used as a biomarker to foresee the patient’s prognosis.GO and KEGG enrichments of the DEGs The CCRCC and its near tissue’s DEGs ’results can be used to forecast the possible function of NPEPL1 and its interactive pathway.Conclusion: NPEPL1’s significantly high expression in CCRCC is not only associated with clinicopathological features of the patient,but closely with the patient’s poor prognosis,thus it can be bused an independent survival risk.Therefore,NPEPL1 can be used as a biomarker to predict the patient’s prognosis.